Literature DB >> 15549443

Current status of hepatic resection for hepatocellular carcinoma.

Katsuhiko Yanaga1.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide. For this disease, a variety of therapeutic measures have been applied, including hepatic resections, total hepatectomy followed by allografting, transarterial chemoembolization, and percutaneous tumor ablative therapy by ethanol, microwave coagulation, and radiofrequency ablation. This article focuses on the current status of hepatic resections for HCC.

Entities:  

Mesh:

Year:  2004        PMID: 15549443     DOI: 10.1007/s00535-004-1422-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  15 in total

1.  Glasgow prognostic score predicts therapeutic outcome after hepatic resection for hepatocellular carcinoma.

Authors:  Hiroaki Shiba; Takashi Horiuchi; Taro Sakamoto; Kenei Furukawa; Yoshihiro Shirai; Tomonori Iida; Yuki Fujiwara; Koichiro Haruki; Katsuhiko Yanaga
Journal:  Oncol Lett       Date:  2017-04-28       Impact factor: 2.967

2.  Prognostic impact of preoperative the branched-chain amino acid to the tyrosine ratio in hepatocellular carcinoma patients after initial hepatectomy.

Authors:  Toru Mizuguchi; Masaki Kawamoto; Makoto Meguro; Yukio Nakamura; Kohei Harada; Kazuharu Kukita; Koichi Hirata
Journal:  J Gastrointest Surg       Date:  2011-05-24       Impact factor: 3.452

3.  Concurrent and subsequent radiofrequency ablation combined with hepatectomy for hepatocellular carcinomas.

Authors:  Dongil Choi; Hyo K Lim; Hyunchul Rhim
Journal:  World J Gastrointest Surg       Date:  2010-04-27

4.  MAGE-3 and MAGE-4 genes as possible markers for early detection of metastases in hepatitis C virus Egyptian patients complicated by hepatocellular carcinoma.

Authors:  Yousri M Hussein; Amal F Ghareib; Randa H Mohamed; Mohamed I Radwan; Wael H Elsawy
Journal:  Med Oncol       Date:  2011-03-31       Impact factor: 3.064

5.  Alkaline phosphatase: does it have a role in predicting hepatocellular carcinoma recurrence?

Authors:  Ming-Chin Yu; Kun-Ming Chan; Chen-Fang Lee; Yun-Shien Lee; Firas Zahr Eldeen; Hong-Shiue Chou; Wei-Chen Lee; Miin-Fu Chen
Journal:  J Gastrointest Surg       Date:  2011-05-04       Impact factor: 3.452

6.  Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (≥10 cm) hepatocellular carcinomas: A clinical study.

Authors:  Nan Bao Zhong; Guang Ming Lv; Zhong Hua Chen
Journal:  Mol Clin Oncol       Date:  2014-06-06

7.  Radiation dose reduction in hepatic multidetector computed tomography with a novel adaptive noise reduction filter.

Authors:  Yoshinori Funama; Kazuo Awai; Osamu Miyazaki; Taiga Goto; Yoshiharu Nakayama; Masamitchi Shimamura; Kumiko Hiraishi; Shinichi Hori; Yasuyuki Yamashita
Journal:  Radiat Med       Date:  2008-04

8.  Radio frequency ablation for hepatocellular carcinoma in cirrhotic patients: prognostic factors for survival.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Marco Sandri; Silvia Pachera; Corrado Pedrazzani; Sebastiano Tasselli; Calogero Iacono
Journal:  J Gastrointest Surg       Date:  2007-02       Impact factor: 3.452

9.  Appraisal of hepatic resection in the treatment of hepatocellular carcinoma with severe thrombocytopenia.

Authors:  Keishi Sugimachi; Yasuharu Ikeda; Morimasa Tomikawa; Akinobu Taketomi; Shuichi Tsukamoto; Katsumi Kawasaki; Shinji Yamamura; Daisuke Korenaga; Yoshihiko Maehara; Kenji Takenaka
Journal:  World J Surg       Date:  2008-06       Impact factor: 3.352

10.  Selection of treatment modality for hepatocellular carcinoma according to the modified Japan Integrated Staging score.

Authors:  Atsushi Nanashima; Junichi Masuda; Satoshi Miuma; Yorihisa Sumida; Takashi Nonaka; Kenji Tanaka; Shigekazu Hidaka; Terumitsu Sawai; Takeshi Nagayasu
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.